The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes bojo different run to imm ! Nice news on sclp well done pleased for you .i know I bang on about dnl but I can trust it and I can sleep at night .one of my other pharma is becoming hardwork after a few good years
You're welcome Bojo. Sometimes you have to look beyond the day to day fluctuations and noise and see the bigger picture.
Obviously the risk remains with biotechs but I try to reduce that risk for my own pf by focusing on late stage ones.
Good to see your doing well on Sclp. I have a mental block that prevents me from buying shares that have risen even 20-30 per cent in a short time frame. It's how I've missed out on some good opportunities including Sclp - that looks like a good one another Tils with lots of projects ongoing.
My approach is the opposite of Nolupus. I'm working on it! Trying to rewire my psychology! Think it's working as I topped up here as well at 63! I wouldn't have done that before having bought at an average of 32p before
With more experience in the markets I hope to get better.
Yes Score,
The picture is pretty clear here IMO. Many boxes ticked and that is why I am happy to add.
50/s to 60/. Is a great price for how we are that’s why I have been buying .I always add on news
Stateside welcome fum is a dream this is real . Was a trader on fum before at 40p always a pattern. There up and down . Great price 62p for the achievement dnl have got I’m buying in some more just want it to settle Nothing but great news of late ok. I was in at 30 but there was a slight risk now most risk is off so paying more is fine as dnl has passed more hurdles
Balanced,
Very helpful information, thank you.
I added again this morning but it took a while to get served...
ATB.
Added at 62.99p. Thank you very much.
(Sold my FUM to pay for it. What dog that has been. Pie in the sky. I was an idiot to hold it so long.)
DNL now my biggest holding.
Scored,
You know more than me, so i have no more to offer , than Stick to your convictions ...
The test of the support zone will be informative :-)
Another thing we are all ready to go , No dreams here like some Parma’s this is the real deal , Cannot think of a better one out there ! To be only the 3rd aim company to get approval is tremendous, Did think USA Israel’s tie up was good for dnl Atb everybody I will enjoy the ride to the end on this one . That’s why I stopped trading it
Balanced66 great write up - My target is two pounds now however if I see more potential it could be ten pound tab IM holding on to mine dnl shares . No lupus your thoughts be appreciated
support zone 62-63p
Will have to buy at that level in any case :-)
I have a few of these giants of the future type shares, hopefully at least one of them fulfills the potential!
Alkindi US - Eton have updated the forecast sales from Dnl's $25 to $100m
Not including the milestone payments from Eton high double digit royalties for Alkindi in US after deduction of some costs will still leave a very high margin - it will nearly all be profit. So if left with £10-£12 million profit just from US sales and not rest of world that would give a pe of 20 and market cap of circa £200 million. But I anticipate the pe will be much higher 30-60 or more so possibilities are huge and then add ROW for Alkindi sales and see if we are not a billion plus company? Then Chronocort from Europe to be added and later from US and further indications from the side studies adding more revenue. Chronocort at peak sales will mean we are a several billion market cap company.
Then the biggy Ditest - we don't need that but if it is successful then we are looking £10 billion plus company.
I don't think we will get to a 10 billion company probably taken over by then.
You need vision to hold shares like this how many will still be holding when this reaches £2 hopefully?
Phase 3 study in US still needs completing. Not sure if they will partner with Eton. If they do Eton may need to raise more money to fund the P3 study if Dnl don't fund themselves. From last half year results RNS:
"Chronocort® US: preparing for pivotal studies
During the past year, Diurnal has also refined its US development strategy for Chronocort®, to reflect both previous feedback from the FDA and its own experience with the European Phase 3 study. The design of the US Phase 3 study has now been optimised based on this information and, shortly after the end of the financial year, Diurnal submitted the updated protocol to the FDA for a Special Protocol Assessment (SPA) meeting. If granted, the SPA potentially offers more certainty for ultimate approval of Chronocort® in the US, assuming that the clinical endpoints of the Phase 3 study are met. The Phase 3 registration study for Chronocort® in the US will recruit up to 150 patients with CAH randomised to either receive Chronocort® twice daily or standard of care. The study is expected to commence once the Group has either secured additional funding to run the study or has identified a US development and commercialisation partner for Chronocort®. Diurnal believes that the preparatory work previously undertaken for this study, including identification of key clinical sites, will substantially accelerate the start-up once the study financing has been secured.
Diurnal is also planning a Phase 2 study design to assess the utility of Chronocort® in AI, which represents a sizeable commercial opportunity in the US of potentially close to $1bn, with a highly favourable competitive landscape. Diurnal has developed a protocol for this study, which it intends to commence alongside the Phase 3 registration study on CAH, subject to funding for either in-house development or with the support of a US partner."
All positive. Market opportunity from European approval alone will be huge and the European market opportunity is bigger financially than the US - see page 12-13 of link below which is from the old Feb 2020 results presentation.
https://www.diurnal.co.uk/media/36801/interim-results-presentation-february-2020-pp.pdf
Chester,
I have re-read the EMA RNS and it of course confirms you are right!
Many Thanks
Hi BOJO2020
I'm sure that Chronocort is going through the European approval first quarter next year an then later to the FDA. DNL still need to sign up a US partner agreement for Chronocort which will probably be a second agreement with Eton.
Chester.
Have we applied for FDA approval on Chronocort, I have been looking through the RNS's and the website. Could not see anything.
Some good consolidation after the recent rise. Look forward to the next news for Chronocort. That's not long to wait now either on the expected q1 2021 approval.
We have an SPA meeting with FDA due as well so there should be news on that as well.
All looking good and professionally run. No worries like other biotechs - funding, phase 2, phase 3 approvals and so on.
CHEAPER than yesterdays buy at 67.7 will add more if she drifts my favourite company